Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2023 - WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc....
Dyne Therapeutics to Present at Investor Conferences in November
November 02, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
October 31, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
- Company Anticipates Reporting Data from Global, Multiple Ascending Dose DELIVER Clinical Trial in the Second Half of 2023 - WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics,...
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
October 11, 2022 16:10 ET
|
Dyne Therapeutics, Inc.
- Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping - - First Presentation of In Vitro Data for...
Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 27, 2022 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event
September 12, 2022 07:00 ET
|
Dyne Therapeutics, Inc.
- Presentation and Discussion with Two Leading Neuromuscular Disease Experts - - Data from DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Anticipated in the Second Half of 2023 - - Refined...
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 06, 2022 07:01 ET
|
Dyne Therapeutics, Inc.
- First Patient Expected to be Dosed in September - - Data from Global, Multiple Ascending Dose ACHIEVE Trial Anticipated in the Second Half of 2023 - - Dyne to Host “Spotlight on the Clinic”...
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
September 06, 2022 07:00 ET
|
Dyne Therapeutics, Inc.
- Data from Global, Multiple Ascending Dose DELIVER Trial Anticipated in the Second Half of 2023 - - Dyne to Host “Spotlight on the Clinic” Virtual Event on September 12 - WALTHAM, Mass., Sept. ...